Core Insights - CMI Media Group has appointed Andy Shaughnessy as SVP of Data Analytics, aiming to enhance actionable analytics for clients across various channels [1] - Andy Shaughnessy brings 15 years of experience in pharma analytics, focusing on omnichannel strategy and advanced analytics [2] - His career includes notable achievements such as multiple awards for analytics excellence and a strong track record in the pharma analytics industry [3] Company Overview - CMI Media Group is a leading healthcare media specialist under WPP, recognized for its innovative contributions to healthcare marketing [5] - The agency offers a range of services including Audience Strategy, Data and Analytics, and Customer Experience, positioning itself as a key resource for top healthcare companies [6] - CMI Media Group has been acknowledged for its inclusivity, talent retention, and employee development, making it one of the best workplaces in the industry [6]

Core Insights - The Zacks Rank system emphasizes earnings estimates and revisions to identify winning stocks, while also considering trends in value, growth, and momentum for strong stock picks [1][2] Value Investing - Value investing is highlighted as a preferred strategy for identifying strong stocks across various market conditions, focusing on traditional analysis of key valuation metrics to find undervalued stocks [2] AMN Healthcare Services - AMN Healthcare Services (AMN) is identified as a strong value stock, currently holding a Zacks Rank of 2 (Buy) and a Value grade of A, indicating its attractiveness to value investors [3] - AMN has a price-to-book (P/B) ratio of 1.17, which is favorable compared to the industry average P/B of 1.58, suggesting that the stock is undervalued [4] - The historical P/B ratio for AMN has ranged from a high of 2.95 to a low of 0.95, with a median of 1.40 over the past year, reinforcing its current valuation status [4] - The combination of AMN's strong earnings outlook and its valuation metrics positions it as an impressive value stock at this time [5]

High quality, highly accessible healthcare For all © 2 0 2 5 A l l R i g h t s R e s e r ve d – D oc Go Disclaimer This presentation is being delivered solely for informational purposes. No representation or warranty, express or implied, is made by DocGo, its affiliates, or any of their respective directors, officers, shareholders, members, partners or representatives as to the accuracy or completeness of any information in this presentation. Except where otherwise indicated, this presentation speaks as of ...

Core Insights - AMN Healthcare has elected Celia Huber to its Board of Directors, bringing over 30 years of experience in healthcare strategy and governance [1][3] - Huber's expertise includes advising healthcare systems and payors on strategy, risk, and performance, aligning with AMN's mission to enhance workforce solutions [2][3] Company Overview - AMN Healthcare is recognized as a leader in total talent solutions for healthcare organizations in the U.S., focusing on solving workforce challenges to improve clinical outcomes [7] - The company offers a comprehensive network of healthcare professionals and a customizable suite of workforce technologies [7] Leadership Background - Celia Huber is a Senior Partner at McKinsey & Company, leading the Board Services Practice in North America, and has extensive experience in governance and organizational transformation [3][5] - Huber has served on various boards and committees, including the AltaMed Foundation and the California Business Roundtable, showcasing her commitment to healthcare and community service [5]

Veradigm (MDRX) Update / Briefing June 24, 2025 08:00 AM ET Speaker0 Greetings, and welcome to the Veradigm Investor Update Conference Call and Webcast. At this time, all participants are in a listen only mode. As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Jenny Jelenis, Vice President, Investor Relations. Jenny, please go ahead. Speaker1 Thank you very much. Good morning, and welcome to the Veradigm update conference call. Our speakers today are Tom Langan, ...

MINNEAPOLIS, June 24, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading provider of regulatory-grade imaging Real-World Data (iRWD), today announced that it has entered into agreements with accredited investors in private placement transactions at $0.42 per share of common stock that resulted in gross proceeds of approximately $3.7 million, before deducting fees and expenses payable by the Company. Certain Company’s founders and directors participated ...

Core Insights - OptimizeRx Corp. has appointed Steve Silvestro, the current CEO, to its Board of Directors effective June 20, 2025, enhancing leadership and execution of value creation plans [1][2][3] Company Leadership - Steve Silvestro joined OptimizeRx in 2019, became CEO in March 2025, and previously served as interim CEO from January 2025 [2][4] - The Board of Directors has recognized Silvestro's leadership and the progress made under his tenure, which has strengthened the company's position and laid a foundation for long-term shareholder value [3] Strategic Direction - Silvestro expressed optimism about OptimizeRx's direction, emphasizing a focus on operational excellence, customer satisfaction, and a strong outlook for 2025 and beyond [3] - The company aims to deepen its value proposition with pharmaceutical partners, accelerate the shift towards a recurring revenue model, and progress towards achieving Rule of 40 performance [3][4] Company Overview - OptimizeRx is a healthcare technology company that connects life science brands with patients and healthcare providers through innovative AI-driven tools [5][6] - The company is committed to privacy-safe, patient-centric technology, partnering with leading pharmaceutical and life sciences companies to transform healthcare [6]

Dr. Kris Radcliff to Highlight MR Spectroscopy and Augmented Intelligence (AI)-Based Platform at State of Spine Surgery Think TankBROOMFIELD, Colo., June 24, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its participation in the upcoming State of Spine Surgery Thi ...

Group 1 - The core viewpoint emphasizes the importance of maternal and child health as a foundation for national health and the necessity of disseminating scientific knowledge to promote it [1][2] - The "2025 People's Good Doctor Maternal and Child Health Science Popularization Action" was launched in March 2025, aiming to enhance public awareness of maternal and child health through expert consensus on nutrition during pregnancy [1][2] - Experts encourage more healthcare professionals to engage in health science communication, creating diverse and authoritative maternal and child health content to improve public awareness [1][2][3] Group 2 - The "Healthy China Action (2019-2030)" includes "Maternal and Child Health Promotion Action" as one of its 15 special actions, highlighting the significance of health education in improving health levels among women and children [2] - The initiative aims to increase awareness of prenatal care and nutrition, ultimately contributing to high-quality childbirth [2][3] - Healthcare professionals are encouraged to utilize their clinical experience to create accessible and engaging health education materials for the public [2][3] Group 3 - Collaboration between medical professionals and enterprises is essential for building a robust ecosystem for maternal and child health science popularization [4] - Bayer's Women's Health Care Initiative aims to provide comprehensive health services and solutions for women, addressing both physical and mental health needs [4] - The list of contributors to the "2025 People's Good Doctor Maternal and Child Health Science Popularization Action" includes various healthcare professionals from different hospitals [6][7][9][10][11]

Core Insights - Medtronic plc has appointed Dr. Joon Lee, CEO of Emory Healthcare, as an independent director on its Board, effective June 18, 2025 [1] - Dr. Lee will contribute to the Science and Technology Committee and Compensation and Talent Committee [1] Company Overview - Medtronic is a global leader in healthcare technology, headquartered in Galway, Ireland, with a mission to alleviate pain, restore health, and extend life [6] - The company employs over 95,000 people across more than 150 countries and addresses 70 health conditions with its technologies [6] Dr. Joon Lee's Background - Dr. Lee has over 25 years of experience at the University of Pittsburgh Medical Center (UPMC), where he held significant roles including Executive Vice President and President of Physician Services [3] - He has a strong background in cardiology, having served as Chief of the Division of Cardiology and founding executive director of the UPMC Heart and Vascular Institute [4] - Dr. Lee's educational credentials include a BA from Dartmouth College and an MD from Duke University, along with extensive training in cardiology at Massachusetts General Hospital [5] Financial and Operational Insights - Emory Healthcare, under Dr. Lee's leadership, generates $7.7 billion in annual revenue and operates 12 hospitals with over 29,000 employees [2] - Dr. Lee also served as Chief Medical Officer of UPMC Insurance Services, which is a $13 billion health insurance division [4] Strategic Vision - Dr. Lee is recognized for his commitment to leveraging data and technology to enhance patient and provider experiences, aligning with Medtronic's mission [2]